AYTU Insider Report: 10,000 Restricted Shares Added by Director

Rhea-AI Filing Summary

Reporting person: Abhinav Jain, a director of AYTU BIOPHARMA, INC. (AYTU), reported a grant of 10,000 restricted shares on 10/03/2025. The restricted shares carry a vesting condition that they vest on 10/03/2026. The filing shows 19,500 shares beneficially owned by the reporting person after the transaction. The transaction is recorded as a non-derivative acquisition at a $0 price, consistent with a restricted stock grant. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 10/07/2025.

Positive

• 10,000 restricted shares granted increases insider alignment with shareholders
• Vesting date specified (10/03/2026), providing a clear one-year retention incentive

Negative

• Modest incremental ownership: post-transaction holdings are 19,500 shares, a limited change in ownership stake

Insights

Corporate Governance Analyst

Director received restricted stock that vests in one year, modestly increasing insider ownership.

The grant of 10,000 restricted shares increases the reporting person’s direct stake to 19,500 shares and aligns the director’s economic interest with shareholder outcomes until vesting on 10/03/2026. The award is recorded as a non-derivative acquisition at a $0 price, indicating compensation rather than an open-market purchase.

Key dependencies include the one-year vesting schedule and any forfeiture conditions tied to continued service. Investors can monitor cumulative insider ownership and future filings for vesting realizations or additional grants within the next 12 months.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JAIN ABHINAV

(Last) (First) (Middle)

C/O AYTU BIOPHARMA, INC.

7900 EAST UNION AVENUE, SUITE 920

(Street)

DENVER CO 80237

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AYTU BIOPHARMA, INC [ AYTU ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/03/2025		A		10,000(1)	A	$0	19,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Grant of restricted stock, which vest on October 3, 2026.

Remarks:

Exhibit 24: Power of Attorney

	/s/ Ryan J. Selhorn as attorney-in-fact for Abhinav Jain	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AYTU director Abhinav Jain report on Form 4 (AYTU)?

He reported a grant of 10,000 restricted shares acquired on 10/03/2025, with vesting on 10/03/2026.

How many AYTU shares does Abhinav Jain beneficially own after the transaction?

The filing shows 19,500 shares beneficially owned following the reported transaction.

Was the restricted stock purchased or granted for AYTU?

The transaction is reported at a $0 price, indicating a restricted stock grant rather than an open-market purchase.

When was the Form 4 signed for the AYTU transaction?

The Form 4 was signed by an attorney-in-fact on behalf of Abhinav Jain on 10/07/2025.

When do the restricted shares vest for the AYTU grant?

The restricted shares vest on 10/03/2026.